Svenja Henning, Lam C Tsoi, Benjamin Klein, Craig Dobry, Celine C Berthier, Amber N Young, Mitra P Maz, Amy Hurst, Rachael Bogle, Johann E Gudjonsson, J Michelle Kahlenberg
{"title":"皮肤性狼疮患者非病变性皮肤及血液干扰素评分。","authors":"Svenja Henning, Lam C Tsoi, Benjamin Klein, Craig Dobry, Celine C Berthier, Amber N Young, Mitra P Maz, Amy Hurst, Rachael Bogle, Johann E Gudjonsson, J Michelle Kahlenberg","doi":"10.1001/jamadermatol.2025.1697","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Interferons (IFNs) play a crucial role in systemic lupus erythematosus (SLE) pathophysiology and are increased in cutaneous lupus erythematosus (CLE) lesions and blood. Recently, IFN-stimulated genes (ISGs) have been shown to be expressed in nonlesional skin of patients with SLE, suggesting that the nonlesional skin functions as an immune-activated site. Whether this is the case in all patients with SLE remains to be understood.</p><p><strong>Objective: </strong>To compare nonlesional skin and peripheral blood mononuclear cell (PBMC) ISG expression in patients with lupus with and without a history of cutaneous lupus erythematosus.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study at a single-center at a tertiary referral center included patients with a history of cutaneous lupus without SLE (CLEwoSLE), patients with SLE with CLE (SLEwCLE), patients with SLE without CLE (SLEwoCLE), and healthy controls (HCs). All SLE patients met the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) classification criteria and cutaneous lupus was diagnosed by a dermatologist. Data analysis occurred from January 2024 to May 2025.</p><p><strong>Main outcomes and measures: </strong>ISG expression in PBMCs and nonlesional skin was assessed via calculation of IFN score.</p><p><strong>Results: </strong>Overall, 74 of 101 participants were female individuals (73%), and the median (IQR) age varied between 44 (41-50) and 64 (53-68) years between groups. IFN scores in PBMCs were higher in SLEwCLE compared with patients with SLEwoCLE. Similarly, SLEwCLE patients showed highest levels of IFN scores in nonlesional skin. IFN scores in PBMCs and nonlesional skin were strongly correlated (r = 0.83, P < .001).</p><p><strong>Conclusion and relevance: </strong>This cross-sectional study found that ISGs, as represented by IFN scores, in nonlesional skin and PBMCs were elevated in patients with lupus with a history of CLE compared with patients without CLE, suggesting that patients with lupus with and without CLE comprise 2 endotypes, with stronger IFN dysregulation occurring in patients with CLE.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"822-827"},"PeriodicalIF":11.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159849/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nonlesional Skin and Blood Interferon Scores Among Patients With a History of Cutaneous Lupus.\",\"authors\":\"Svenja Henning, Lam C Tsoi, Benjamin Klein, Craig Dobry, Celine C Berthier, Amber N Young, Mitra P Maz, Amy Hurst, Rachael Bogle, Johann E Gudjonsson, J Michelle Kahlenberg\",\"doi\":\"10.1001/jamadermatol.2025.1697\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Interferons (IFNs) play a crucial role in systemic lupus erythematosus (SLE) pathophysiology and are increased in cutaneous lupus erythematosus (CLE) lesions and blood. Recently, IFN-stimulated genes (ISGs) have been shown to be expressed in nonlesional skin of patients with SLE, suggesting that the nonlesional skin functions as an immune-activated site. Whether this is the case in all patients with SLE remains to be understood.</p><p><strong>Objective: </strong>To compare nonlesional skin and peripheral blood mononuclear cell (PBMC) ISG expression in patients with lupus with and without a history of cutaneous lupus erythematosus.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study at a single-center at a tertiary referral center included patients with a history of cutaneous lupus without SLE (CLEwoSLE), patients with SLE with CLE (SLEwCLE), patients with SLE without CLE (SLEwoCLE), and healthy controls (HCs). All SLE patients met the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) classification criteria and cutaneous lupus was diagnosed by a dermatologist. Data analysis occurred from January 2024 to May 2025.</p><p><strong>Main outcomes and measures: </strong>ISG expression in PBMCs and nonlesional skin was assessed via calculation of IFN score.</p><p><strong>Results: </strong>Overall, 74 of 101 participants were female individuals (73%), and the median (IQR) age varied between 44 (41-50) and 64 (53-68) years between groups. IFN scores in PBMCs were higher in SLEwCLE compared with patients with SLEwoCLE. Similarly, SLEwCLE patients showed highest levels of IFN scores in nonlesional skin. IFN scores in PBMCs and nonlesional skin were strongly correlated (r = 0.83, P < .001).</p><p><strong>Conclusion and relevance: </strong>This cross-sectional study found that ISGs, as represented by IFN scores, in nonlesional skin and PBMCs were elevated in patients with lupus with a history of CLE compared with patients without CLE, suggesting that patients with lupus with and without CLE comprise 2 endotypes, with stronger IFN dysregulation occurring in patients with CLE.</p>\",\"PeriodicalId\":14734,\"journal\":{\"name\":\"JAMA dermatology\",\"volume\":\" \",\"pages\":\"822-827\"},\"PeriodicalIF\":11.0000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159849/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jamadermatol.2025.1697\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamadermatol.2025.1697","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Nonlesional Skin and Blood Interferon Scores Among Patients With a History of Cutaneous Lupus.
Importance: Interferons (IFNs) play a crucial role in systemic lupus erythematosus (SLE) pathophysiology and are increased in cutaneous lupus erythematosus (CLE) lesions and blood. Recently, IFN-stimulated genes (ISGs) have been shown to be expressed in nonlesional skin of patients with SLE, suggesting that the nonlesional skin functions as an immune-activated site. Whether this is the case in all patients with SLE remains to be understood.
Objective: To compare nonlesional skin and peripheral blood mononuclear cell (PBMC) ISG expression in patients with lupus with and without a history of cutaneous lupus erythematosus.
Design, setting, and participants: This cross-sectional study at a single-center at a tertiary referral center included patients with a history of cutaneous lupus without SLE (CLEwoSLE), patients with SLE with CLE (SLEwCLE), patients with SLE without CLE (SLEwoCLE), and healthy controls (HCs). All SLE patients met the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) classification criteria and cutaneous lupus was diagnosed by a dermatologist. Data analysis occurred from January 2024 to May 2025.
Main outcomes and measures: ISG expression in PBMCs and nonlesional skin was assessed via calculation of IFN score.
Results: Overall, 74 of 101 participants were female individuals (73%), and the median (IQR) age varied between 44 (41-50) and 64 (53-68) years between groups. IFN scores in PBMCs were higher in SLEwCLE compared with patients with SLEwoCLE. Similarly, SLEwCLE patients showed highest levels of IFN scores in nonlesional skin. IFN scores in PBMCs and nonlesional skin were strongly correlated (r = 0.83, P < .001).
Conclusion and relevance: This cross-sectional study found that ISGs, as represented by IFN scores, in nonlesional skin and PBMCs were elevated in patients with lupus with a history of CLE compared with patients without CLE, suggesting that patients with lupus with and without CLE comprise 2 endotypes, with stronger IFN dysregulation occurring in patients with CLE.
期刊介绍：
JAMA Dermatology is an international peer-reviewed journal that has been in continuous publication since 1882. It began publication by the American Medical Association in 1920 as Archives of Dermatology and Syphilology. The journal publishes material that helps in the development and testing of the effectiveness of diagnosis and treatment in medical and surgical dermatology, pediatric and geriatric dermatology, and oncologic and aesthetic dermatologic surgery.
JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. It is published online weekly, every Wednesday, and in 12 print/online issues a year. The mission of the journal is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, with the aim of enabling dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care.
The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. It also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists, aiming to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists.
JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
